Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birelentinib and Venetoclax in CLL/SLL
NCT07154264Phase 2Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of birelentinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Incidence of Adverse Events and Progression-Free Survival rate at 2 years. Started Sep 2025; status: recruiting.
02
Drugs
birelentinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07154264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07154264.